PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials - Summary - MDSpire

PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials

  • By

  • Zhilong Huang

  • Wenwen Li

  • Minghong Li

  • Yifu Huang

  • Yongjiang Lu

  • Jiahang Hu

  • June 1, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of PD-1/PD-L1 inhibitors combined with chemotherapy as first-line treatment for advanced or metastatic endometrial cancer.

Key Findings:
  • relative_risks
Interpretation:

Remove unsupported conclusions and rephrase to reflect findings directly from the source.

Limitations:
  • specificity
Conclusion:

Revise to reflect only the findings presented in the source without unsupported claims.

Original Source(s)

PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials

  • by Zhilong Huang, Wenwen Li, Minghong Li, Yifu Huang, Yongjiang Lu, Jiahang Hu

  • June 1, 2026

Related Content

The role of artificial intelligence in postoperative clinical decision-making for pancreatic cancer: a pilot study

Chemical priming potentiates mesothelin-targeting chimeric antigen receptor-engineered NK-92 antitumor activity by improving tumor trafficking and cytotoxic killing dynamics

Pathological diagnosis of thyroid nodules directly from ultrasonography by a weakly supervised deep learning framework